ACET

2.16012.20%
CS

Chen Schor

CEO, President & Director

Mr. Chen Schor, MBA, BA, CPA, serves as Chair of Carbon Biosciences, Inc. He has been the Chief Executive Officer, President & Director at Adicet Bio, Inc since September 15, 2020. He was a Co-Founder of resTORbio, Inc. and served as its President and Chief Executive Officer since incorporation in July 2016 until September 2020. He serves as Independent Director at Karyopharm Therapeutics Inc since November 25, 2020. Mr. Schor served as Secretary of resTORbio, Inc. and serves as its Principal Financial and Accounting Officer since July 31, 2020. Mr. Schor serves as Chief Business Officer at Follica, Inc. He has leadership experience in biotechnology, medical devices, business development and private equity. He served as the Chief Executive Officer, President and Director at Synta Pharmaceuticals Corp. since May 7, 2015 until July 2016 and served as its Chief Operating Officer and Executive Vice President from December 08, 2014 to May 7, 2015. From September 2012 to December 2014, Mr. Schor served as the President and Chief Executive Officer at Novalere, Inc. He served as the Chief Business Officer of Eleven Biotherapeutics Inc from September 2011 to October 2012. Mr. Schor joined Eleven Biotherapeutics on September 22, 2011. Mr. Schor has led biotechnology companies across all stages, from formation and early stage discovery to leading a publicly traded multi-product company with significant external partnerships. He served as the Chief Business Officer and Senior Vice President of Predix Pharmaceuticals Holdings, Inc. He served as the Chief Business Officer of EPIX Pharmaceuticals, Inc. from August 16, 2006 to March 23, 2009. Mr. Schor served as the Chief Business Officer of Predix Pharmaceuticals, Inc. from January 2004 to August 2006 and also served as its Senior Vice President. Prior to co-founding resTORbio and closing its merger with Adicet, Mr. Schor led the turnaround of Synta Pharmaceuticals and its reverse merger with Madrigal Pharmaceuticals. From 1998 to December 2003, he served as a Partner, Life Sciences at The Yozma Group (Yozma Venture Capital Group) where he led the foundation and growth of multiple therapeutic companies from inception to commercial success and also served as its Principal and Chief Financial Officer. From March 2009 until September 2011, he served as a Vice President of Business Development, Global Branded Products of Teva Pharmaceutical Industries Limited and served as its Vice President of Global Branded Business Development and Pipeline Management. Mr. Schor leads corporate and business development initiatives including oversight and establishment of strategic collaborations for EPIX programs and assets and strategic planning activities. He also served at ESC Medical, Elbit and Elscint. He held positions at BDO consultants from 1996 to 1998. He has vast experience leading biotech companies across all stages, from formation, building a team and early stage discovery to a publicly traded multi-product company with significant big pharma partnerships. He served as a Director of Novalere, Inc. He served as a Director of resTORbio, Inc. since July 2016. He served as Director of Brainstorm Cell Therapeutics Inc., since August 22, 2011 until March 2020. Mr. Schor served as an Auditor of Arthur Andersen & Co. from 1995 to 1996. He served as a Director at Can-Fite BioPharma Ltd. since 1998. He served as a Director of Gelesis, Inc. He served as a Director of Predix Pharmaceuticals Holdings Inc. from August 2003 to December 2003. He served as a Member of the Board of directors of Predix Pharmaceuticals Ltd. from November 2000 to August 2003 and Predix Pharmaceuticals, Inc. from September 2001 to August 2003. Mr. Schor is a Certified Public Accountant. He holds B.A. in Economics and Accounting from Haifa University and a B.A. in Biology from Tel Aviv University and an M.B.A. Degree from Tel Aviv University.

Positions